LT3.F AXOGEN INC. DL -01

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
50.34 EUR
Close of Nov 12, 2026
19.90 52.20
Market cap
EUR 3.01B
P/E
-
P/B
6.94x
ROE
-5.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LT3.F undervalued?

Graham number

The Graham number of AXOGEN INC. DL -01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AXOGEN INC. DL -01 fundamental analysis

No fundamental analysis for AXOGEN INC. DL -01 yet.

AXOGEN INC. DL -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AXOGEN INC. DL -01

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product us…

Full company profile